Tourette Syndrome Clinical Trial
Official title:
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286)
Verified date | October 2017 |
Source | Baylor College of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Previous studies using topiramate in Tourette subjects have shown that with the use of this medication subjects report that their tics get better. The purpose of this study is to study if topiramate improves the symptoms of Tourette syndrome, such as motor tics, or other associated symptoms such as attention or obsessive-compulsive problems.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 2008 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Subjects must continue to meet the specific inclusion criteria outlined in either CAPSS-176 or CAPSS-198 to enroll in this protocol. - Subjects must have completed the Double-Blind Phase or discontinued the Double-Blind Phase after a minimum of 6 weeks due to lack of efficacy (defined by a CGI improvement score of >6 [much worse or very much worse]) in either CAPSS-176 or CAPSS-198. - Subjects or their parents/guardians, must be able to read and comprehend written instructions and willing to complete all scales and assessments required by this protocol. - After full explanation of the study, subjects, or their parent/legally authorized representatives, must demonstrate their willingness to participate by signing an informed consent form. If applicable, pediatric subjects capable of giving assent must sign the assent form. - Subjects must continue their current treatment for tics, treatment of comorbid symptoms or treatment of A-D/HD at the dose level established prior to entry in the Double-Blind Phase of CAPSS-176 or CAPSS-198. Exclusion Criteria: - Subjects must continue to meet the specific exclusion criteria outlined in either CAPSS-176 or CAPSS-198 to enroll in this protocol. - Subjects who have SGOT and/or SGPT levels greater than 2 times the upper limit of the normal range from the last visit in either CAPSS-176 or CAPSS-198 will not be permitted to enroll in the current study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Baylor College of Medicine | Ortho-McNeil Janssen Scientific Affairs, LLC |
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):70-3. doi: 10.1136/jnnp.2009.185348. Epub 2009 Sep 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in TTS | A component of the Yale Global Tic Severity Scale (YGTSS), the change from baseline in Total Tic Score (TTS) at visit 5 (day 70) is the pre-defined primary endpoint. The Total Tic Score is a summation of the Total Motor Tic and Total Phonic Tic Scores. The Overall Impairment Rating is rated on a 50-point scale anchored by 0 (No impairment) and 50 (Severe impairment). | baseline to Day 70 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04851678 -
Longitudinal Impact of Stressors in Adults With Tourette Syndrome
|
||
Completed |
NCT02605902 -
Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders
|
N/A | |
Completed |
NCT04007913 -
Incorporating teleCBIT Into a Hospital-Based Tic Program
|
N/A | |
Completed |
NCT02900144 -
Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)
|
N/A | |
Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
Completed |
NCT02256475 -
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT01329198 -
Brain Stimulation for the Treatment of Tourette Syndrome
|
N/A | |
Terminated |
NCT00952601 -
Pilot Study of the Modified Atkins Diet for Tourette Syndrome
|
Phase 1 | |
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00206323 -
A Randomized, Placebo-controlled, Tourette Syndrome Study.
|
Phase 3 | |
Completed |
NCT00004376 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
|
Phase 3 | |
Completed |
NCT04498364 -
Extinction Learning in Adults With Tourette Syndrome
|
N/A | |
Completed |
NCT00755339 -
Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
|
||
Completed |
NCT03325010 -
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT01702077 -
Neurofeedback for Tourette Syndrome
|
N/A | |
Completed |
NCT01719523 -
Open-Trial of EPI-743 for Adults With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT00231985 -
Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
|
Phase 2 | |
Terminated |
NCT03732534 -
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
Completed |
NCT03625453 -
Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder
|
Phase 2 |